ChemoCentryx $346.8 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …
NeoGenomics $300 million offerings of stock and convertible senior notes
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…
Coherus BioSciences $200 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189.75 million aggregate principal amount of its 2.75% convertible…
Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 16,000,000 shares of common stock…
Alector $240 million stock offering
Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…
Ardelyx, Inc. $144 Million Follow-On Public Offering
Davis Polk advised the joint book-running managers for the public offering of common stock by Ardelyx, Inc for gross proceeds of approximately $144 million, including the full exercise…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…